Cambridge, UK 1/22/18—Reagent and tool provider Abcam has exclusively licensed rights to the RUO–only product portfolio of Spring Bioscience, a Roche company. The 760 unique products consist of 243 recombinant rabbit monoclonal antibodies as well as Spring Proprietary Clones, optimized for IHC, and monoclonal and polyclonal antibodies. In addition, Abcam gained exclusive rights to all future RUO products developed by Spring Bioscience for which Roche requests commercialization. “This agreement represents an exciting step in the ongoing collaborative and long-term relationship between Abcam and Roche,” said Abcam Chief Executive Alan Hirzel. “Abcam is excited to partner with Spring Bioscience, commonly recognized as a leading manufacturer of immunohistochemistry antibodies, furthering Abcam’s mission to provide customers with the highest-quality recombinant antibodies for their research.” The products will be available under the Abcam brand starting February 21.

Roche retains the rights to the antibodies for internal research, companion diagnostics and IVDs. The agreement enhances Roche’s antibody offerings by adding an exclusive supplier and bolstering its IHC business. The IHC business is part of Abcam’s expansion outside the antibody business. (For more on Abcam, see Abcam and Tecan Present at JP Morgan Conference).